This is in line with previous studies suggesting that the antiangiogenic activity of low molecular weight fucoidan (LMWF) in bladder cancer is associated with suppressing HIF-1/VEGF- signaling pathway (Chen et al., 2015). This evidence concerns the gene VEGFA and urinary bladder carcinoma.